This article is more than 5 years old. Information may no longer be current.
Bone resorption, inflammatory markers may identify patients at risk for osteolysis
Click Here to Manage Email Alerts
Results published in The Journal of Orthopaedic Research showed combination of a bone resorption marker and an inflammatory marker had high accuracy in differentiating patients who developed peri-implant osteolysis.
D. Rick Sumner, PhD, FAAA, and colleagues examined biomarkers at radiographic diagnosis, annually for 6 years preceding diagnosis, at the first postoperative sampling point and preoperatively from a repository of urine samples collected prior to and annually after total hip arthroplasty among 26 patients. Biomarkers measured included free deoxypyridinoline, cross-linked N-telopeptides, interleukin (IL)-6, IL-8, osteoprotegerin, alpha-crosslaps and beta-crosslaps.
Results showed 16 patients developed osteolysis and 10 patients did not develop the condition. Researchers noted free deoxypyridinoline had the highest ability to predict osteolysis as an individual biomarker. The osteolysis group had elevated alpha-crosslaps at 3 years prior to diagnosis and at diagnosis. Similarly, researchers found patients in the osteolysis group had elevated IL-6 levels at 6 and 4 years prior to diagnosis and at diagnosis.
“We have identified two markers that may be helpful in identifying patients at risk for developing peri-implant osteolysis following total hip replacement,” Sumner told Healio.com/Orthopedics. “Follow-up studies involving larger cohorts will be needed to verify the findings.” – by Casey Tingle
Disclosures: The authors report grant support from the Orthopaedic Research and Education Foundation, National Institute of General Medical Sciences and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Click Here to Manage Email Alerts